

Post Traumatic Stress Disorder Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Market Report | 2023-01-23 | 111 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The post traumatic stress disorder treatment market is expected to register a CAGR of more than 4% over the forecast period (2022-2027).

The COVID-19 pandemic is an unprecedented health concern that has significantly impacted the posttraumatic stress disorder (PTSD) treatment market. There are several studies conducted that indicate that COVID-19 increases the risk of PTSD, and this has led to an increase in demand for PTSD treatment. For instance, an article titled, "COVID-19 and Posttraumatic Stress Disorder: The Perfect 'Storm' for Mental Health (Review)" published in August 2021 demonstrated that COVID-19 has a substantial impact on mental health and poses a significant risk to the development of trauma-related disorders, including PTSD among individuals who are most vulnerable, such as children, adolescents and COVID-19 survivors. Additionally, as per an article titled, "Posttraumatic Stress Disorder in Patients After Severe COVID-19 Infection", published in February 2021, a cross-sectional study found a PTSD prevalence of 30.2% after acute COVID-19 infection, which is in line with findings in survivors of the previous coronavirus illnesses compared with findings reported after other types of collective traumatic events. Such studies indicate that the demand for PTSD treatment boosted amid the pandemic. Thus, the COVID-19 pandemic has positively impacted market growth.

The growth of the market can be attributed to the factors such as the increasing burden of post-traumatic stress disorder (PTSD) worldwide, the rise in the number of clinical trials pertaining to PTSD treatment as well as increasing research and development of novel therapies and drugs for PTSD.

The increasing burden of post-traumatic stress disorder is driving the demand for treatment that is majorly contributing to the market growth. As per the article titled, "Global Burden of Posttraumatic Stress Disorder and Major Depression in Countries

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Affected by the War: a Systematic Review and Meta-analysis" published in July 2021 reported that out of twenty-two surveys for PTSD, 13 surveys for major depression (MD) and six surveys on the comorbidity of post-traumatic stress disorder and MD were included. As per the study, random effects meta-analyses yielded a point prevalence of 26.51% for post-traumatic stress disorder. The study also stated that the extrapolation yielded 316 million adult war survivors globally who suffered from post-traumatic stress disorder and/or Major depression. Thus, the statistics from the study indicate the rising demand for post-traumatic stress disorder treatment.

Additionally, as per an April 2022 update by SANE Australia, in Australia, around 1-2% of adults experience post-traumatic stress disorder each year, while approximately 12% experience PTSD in their lifetime. This further indicates the significantly growing demand for post-traumatic stress disorder treatment.

However, the rise in the number of clinical trials is also contributing to the market growth. For instance, in June 2020, SIU School of Medicine launched a clinical trial to study the safety and efficacy of an investigational drug for post-traumatic stress disorder. Furthermore, in June 2021, ANANDA Scientific Inc., biotech pharmaceutical company, and NYU Grossman School of Medicine today reported the first patient was enrolled in a clinical trial evaluating Nanteia A1002N5S, an investigational drug using cannabidiol in ANANDA's proprietary Liquid Structure delivery technology as a treatment for Post-Traumatic Stress Disorder (PTSD) symptoms and Neurocognitive Impairment in patients with post-traumatic stress disorder and with post-traumatic stress disorder comorbid with Traumatic Brain Injury (TBI). Thus, due to the above-mentioned factors, the market is expected to grow significantly over the forecast period.

However, side effects associated with post-traumatic stress disorder treatment and the high cost of the treatment are the major factors hindering the market growth.

Post Traumatic Stress Disorder Market Trends

Antidepressants Segment is Expected to Hold a Significant Market Share in the Post Traumatic Stress Disorder Treatment Market

By drug class, antidepressants are expected to hold a significant share in the market. Antidepressants are medications used to treat post-traumatic stress disorder (PTSD). These medications aid in relieving symptoms of depression, anxiety, sleep problems, and concentration. The selective serotonin reuptake inhibitor (SSRI) medications sertraline (Zoloft) and paroxetine (Paxil) are approved by the Food and Drug Administration (FDA) for PTSD treatment.

Alternative medications may sometimes be used off-label to treat post-traumatic stress disorder. However, current guidelines do not recommend these medications to be used initially for post-traumatic stress disorder treatment. These medications can include antidepressants like nefazodone (Serzone), imipramine (Tofranil), and phenelzine (Nardil). However, current guidelines do not recommend these medications to be used initially for post-traumatic stress disorder treatment and include antidepressants such as nefazodone (Serzone), imipramine (Tofranil), and phenelzine (Nardil). Thus, the segment is expected to witness healthy growth over the forecast period.

The industry players are adopting competitive strategies, such as mergers & acquisitions, distribution channel enhancement, new product development, and research & development partnerships, to develop effective antidepressant drugs and hence, sustain themselves in the competition. For instance, in March 2022, Sun Pharma entered into an exclusive patent licensing agreement with Danish drugmaker Lundbeck to market and distribute its own version of antidepressant medication Vortioxetine in India under the brand name Vortidifm. Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.

Also, in June 2021, Sage Therapeutics, Inc. and Biogen Inc. announced that the WATERFALL Study in patients with MDD met its

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

primary endpoint with zuranolone(SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score. LS means (SE) change from baseline in HAMD-17 total score at Day 15 for patients who received zuranolone 50 mg was -14.1 (0.51) compared with -12.3 (0.50) for patients who received placebo. Thus, such product developments are predicted to offer a potential growth platform for antidepressants.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

Within North America, the United States has held the major share of the market. The major factors propelling the market growth in the country are the increasing burden of post-traumatic stress disorder, growth in research and development activities as well as presence of strong and established market players.

The high burden of Post-traumatic stress disorder is driving the demand for its treatment in the country. For instance, as per an August 2020 update by the American Psychiatric Association, Post-traumatic stress disorder affects approximately 3.5 percent of United States adults every year, and an estimated one in 11 people will be diagnosed with Post-traumatic stress disorder in their lifetime, and women are twice as likely as men to have Post-traumatic stress disorder.

Moreover, in June 2021, Tarzana Treatment Centre celebrated National Post-traumatic stress disorder Awareness Day in the United States, a point in time when more Americans than ever before are suffering from post-traumatic stress disorder. Thus, such developments indicate the rising awareness regarding Post-traumatic stress disorder that is increasing the demand for its treatment.

Also, the rising number of clinical trials for new drug development for the treatment of post-traumatic stress disorder treatment is expected to drive the regional market growth over the forecast period. For instance, in January 2021, Jazz Pharmaceuticals plc reported the first patient had been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.

Post Traumatic Stress Disorder Market Competitor Analysis

The Post Traumatic Stress Disorder Treatment Market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Lupin Limited, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc. and Merck KGaA.

Additional Benefits:

- The market estimate (ME) sheet in Excel format

Table of Contents:

1 INTRODUCTION

1.1 Study Assumptions and Market Definition

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Burden of Post-Traumatic Stress Disorder (PTSD) Worldwide

4.2.2 Rise in Number of Clinical Trials Pertaining to Post-Traumatic Stress Disorder (PTSD) Treatment

4.2.3 Increasing Research and Development for Novel Therapies and Drugs

4.3 Market Restraints

4.3.1 Side Effects Associated with Post-Traumatic Stress Disorder Treatment

4.3.2 High Cost of the Treatment

4.4 Porter's Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

5.1 By Drug Class

5.1.1 Antidepressants

5.1.2 Anti-anxiety Drugs

5.1.3 Antipsychotics

5.1.4 Other Drug Classes

5.2 By Patient

5.2.1 Adult

5.2.2 Children

5.3 By Distribution Channel

5.3.1 Hospital Pharmacies

5.3.2 Retail Pharmacies

5.3.3 Other Distribution Channel

5.4 Geography

5.4.1 North America

5.4.1.1 United States

5.4.1.2 Canada

5.4.1.3 Mexico

5.4.2 Europe

5.4.2.1 Germany

5.4.2.2 United Kingdom

5.4.2.3 France

5.4.2.4 Italy

5.4.2.5 Spain

5.4.2.6 Rest of Europe

5.4.3 Asia-Pacific

5.4.3.1 China

5.4.3.2 Japan

5.4.3.3 India

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East
 - 5.4.4.1 GCC
 - 5.4.4.2 South Africa
 - 5.4.4.3 Rest of Middle-East
- 5.4.5 South America
 - 5.4.5.1 Brazil
 - 5.4.5.2 Argentina
 - 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
 - 6.1.1 Jazz Pharmaceuticals
 - 6.1.2 Mydecine Innovations Group
 - 6.1.3 Tonix Pharmaceuticals
 - 6.1.4 Otsuka Pharmaceutical Co., Ltd.
 - 6.1.5 Lupin Limited
 - 6.1.6 Teva Pharmaceutical Industries Ltd.
 - 6.1.7 Merck KGaA
 - 6.1.8 Pfizer Inc.
 - 6.1.9 Aurobindo Pharma Limited
 - 6.1.10 GlaxoSmithKline plc
 - 6.1.11 Viatris Inc.
 - 6.1.12 Jubilant Pharmova

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Post Traumatic Stress Disorder Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Market Report | 2023-01-23 | 111 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com